LBA13_PR - Array CGH and DNA sequencing to personalize therapy for metastatic breast cancer: A prospective National trial (UNICANCER SAFIR-01)

Date 01 October 2012
Event ESMO Congress 2012
Session Breast cancer, metastatic
Topics Personalised/Precision medicine
Translational Research
Breast Cancer
Basic Principles in the Management and Treatment (of cancer)
Presenter Fabrice André
Authors F. André1, T. Bachelot2, M. Campone3, M. Arnedos Ballester4, F. Commo1, A. Gonçalves5, C. Levy6, J. Ferrero7, L. Lacroix1, V. Dieras8, F. Dalenc9, D. Gentien10, M. Lacroix11, Q. Wang12, J. Adelaide13, M. Jimenez14, H. Bonnefoi15
  • 1Breast Cancer Unit, Department Of Medical Oncology, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif CEDEX/FR
  • 2Centre Léon Bérard, 69008 - Lyon/FR
  • 3Medical Oncology, Centre René Gauducheau (ICO) Institut de Cancerologie de l'Ouest, 44805 - St Herblain CEDEX/FR
  • 4Department Of Medicine; Breast Unit, Institut Gustave Roussy, FR-94805 - Villejuif/FR
  • 5Medical Oncology, Paoli Calmettes, 13009 - Marseille/FR
  • 6Sénologie, Centre François BACLESSE, Caen/FR
  • 7Departement D'oncologie Medicale, Centre Antoine Lacassagne, Nice/FR
  • 8Department Of Medical Oncology, Clinical Trial Unit, Institut Curie, 75005 - Paris/FR
  • 9Oncologie Médicale, Centre Claudius Regaud, Toulouse/FR
  • 10Translationnal Laboratory, Institut Curie, Paris/FR
  • 11Pathology, centre claudius regaud, toulouse/FR
  • 12Biology, centre leon berard, lyon/FR
  • 13Biology, centre paoli calmette, marseille/FR
  • 14R&d, Unicancer, 75013 - Paris/FR
  • 15Oncology, bergonie, bordeaux/FR


Background: Breast cancer includes large number of actionable genomic alterations. Each of these alterations characterizes individually a rare genomic entity. In the present study, we have used array CGH (aCGH) and Sanger sequencing to direct patients to specific targeted agents.

Patients and methods: Four hundred patients with metastatic breast cancer from 18 centers were planned to be included in the SAFIR01 trial, which started in May 2011. Following inclusion, biopsy of a metastatic site is performed and DNA
extracted provided that the sample contains >50% cancer cells. Biopsy is performed in patients who do not present a progressive disease at the time of inclusion. Tumoral DNA is sent from the investigation center to one of the 5 genomic